Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

Ulrike Leiter; Carmen Loquai; Lydia Reinhardt; David Rafei‐Shamsabadi; Ralf Gutzmer; Katharina C. Kaehler; Lucie Heinzerling; Jessica C. Hassel; Valerie Glutsch; Judith Sirokay; Nora Schlecht; Albert Rübben; Thilo Gambichler; Kerstin Schatton; Claudia Pfoehler; Cindy Franklin; Patrick Terheyden; Sebastian Haferkamp; Peter Mohr; Lena Bischof; Elisabeth Livingstone; Lisa Zimmer; Michael Weichenthal; Dirk Schadendorf; Andreas Meiwes; Ulrike Keim; Claus Garbe; Jürgen C. Becker; Selma Ugurel

doi:10.1136/jitc-2020-000897

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

ICI therapy showed efficacy in advanced patients with skin cancer with a concomitant hematological malignancy. Compared with patients without hematological malignancy, the observed ICI therapy outcome was impaired in cSCC, but not in MM or MCC patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leiter et al. (2020) studied this question.

synapsesocial.com/papers/69d88908c025a7c015bedfb0 https://doi.org/10.1136/jitc-2020-000897

View Full Paper

Ask AI

Bookmark

Share

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

Ask about this paper

Abstract

Discussion

Cite This Study

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading